Search results for "new obesity drug"

Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.6% in Phase 3 clinical trials, though it did...
High Efficacy and Increased Convenience: The Three Obesity Drugs Awaiting FDA Approval

High Efficacy and Increased Convenience: The Three Obesity Drugs Awaiting FDA Approval

Since the World Health Organization recommended the use of obesity medications for adults last December, the market is expected to heat up even...
Kyungpook National University Hospital Team Wins Back-to-Back Awards at International Congress

Kyungpook National University Hospital Team Wins Back-to-Back Awards at International Congress

A research team led by Professor Yoon Jong-pil of the Department of Orthopedic Surgery at Kyungpook National University...
Daewoong Pharmaceutical to Build Aseptic Manufacturing Facility for Semaglutide Microneedle Patch

Daewoong Pharmaceutical to Build Aseptic Manufacturing Facility for Semaglutide Microneedle Patch

Daewoong Pharmaceutical is accelerating efforts to secure Good Manufacturing Practice approval and establish an...
Lexraza Developer and Lilly Obesity Chief to Headline Global Clinical Trial Summit in Seoul

Lexraza Developer and Lilly Obesity Chief to Headline Global Clinical Trial Summit in Seoul

What will it take to build on the success of Lexraza, South Korea’s landmark lung cancer drug, and propel it into the...
Hanmi’s ‘Epe’ Wins MFDS Approval, Becoming South Korea’s First Homegrown GLP-1 Obesity Drug

Hanmi’s ‘Epe’ Wins MFDS Approval, Becoming South Korea’s First Homegrown GLP-1 Obesity Drug

A domestically developed therapy has entered South Korea’s obesity treatment market, long dominated by imported...
From Returned Candidate to Homegrown Breakthrough: Hanmi’s ‘Epe’ Prepares to Challenge Wegovy and Mounjaro

From Returned Candidate to Homegrown Breakthrough: Hanmi’s ‘Epe’ Prepares to Challenge Wegovy and Mounjaro

Efpeglenatide, a drug candidate whose development rights were once returned by a global pharmaceutical giant, is...
Samsung Biologics to Raise ₩3 Trillion in Rights Offering to Fund ₩2.7 Trillion Acquisition of PolyPeptide Group

Samsung Biologics to Raise ₩3 Trillion in Rights Offering to Fund ₩2.7 Trillion Acquisition of PolyPeptide Group

Samsung Biologics is proceeding with a 3 trillion won ($2.25 billion) rights offering, directing approximately 90% of...
Does Wegovy Triple Depression Risk? Real-World Data from Korean Hospitals Yields Nuanced Findings

Does Wegovy Triple Depression Risk? Real-World Data from Korean Hospitals Yields Nuanced Findings

A recent observational study indicates that individuals taking popular GLP-1 receptor agonist obesity medications may...
Kyungdong Pharmaceutical and AUL Bio Seek Phase 1 Approval for Once-Monthly Obesity Drug AUL009

Kyungdong Pharmaceutical and AUL Bio Seek Phase 1 Approval for Once-Monthly Obesity Drug AUL009

Kyungdong Pharmaceutical announced Sept. 2 that it has submitted an investigational new drug application to the...